18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

PRIMARY OBJECTIVES:

I. Using FLT PET/CT as a measure of cellular proliferation, assess tissue proliferation in
disease sites of brain tumor patients before therapy (surgery, chemotherapy or radiotherapy
or any combination of these).

II. Determine level of change in cellular proliferation compared with baseline (scan 1) in
brain tumors at mid-therapy (scan 2), after completion of therapy (scan 3) and in the
clinical follow-up period (scan 4), when possible.

III. Correlate levels of cellular proliferation measured by FLT PET/CT at baseline and
treatment-induced changes in brain tumor proliferation with clinical response status
(clinical categories are complete remission, lesser degrees of response/stable disease, and
no response).

SECONDARY OBJECTIVES:

I. Assess spatial heterogeneity of FLT uptake to identify local differences in brain tumor
disease burden.

OUTLINE:

Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of
therapy, and 1 year after completion of therapy or time of suspected recurrence.

After completion of study, patients are followed for up to 7 years.

Inclusion Criteria:

- Have a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or
metastatic) by standard clinical diagnosis such as pathology or imaging

- Planned for treatment with radiation, chemotherapy and surgical resection or any of
these treatment strategies combined

Exclusion Criteria:

- Inability to provide informed consent

- Pregnancy

- Inability to lie still for the imaging study

- Weight over 350 lbs.